Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

This is a randomized, multicenter, multinational, double-blind, integrated pharmacokinetics (PK) and efficacy similarity study to compare the PK, efficacy, safety, and immunogenicity of MB12 versus Keytruda® in combination with pemetrexed-platinum chemotherapy as first-line treatment in patients with metastatic non-squamous NSCLC.

Participants needed: 726
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: mAbxience Research S.L.Updated: Mar 11, 2026Locations: 151
Eligibility criteria

Adult male/female patients ≥18 years old at the time of signing the informed con... [+5]

Predominantly squamous cell histology NSCLC. Mixed tumors will be categorized by... [+6]

Read more
Status: Recruiting

Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma

This is a randomised, multicentre, multinational, double-blind, integrated study to sompare the pharmacokinetics, efficacy, safety, and immunogenicity of MB11 versus Opdivo® in subjects with previously untreated advanced (unresectable or Metastatic) Melanoma

Participants needed: 632
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: mAbxience Research S.L.Updated: Jan 21, 2026Locations: 19
Eligibility criteria

Age ≥18 years at the time of signing the informed consent (or adulthood where th... [+5]

At least 1 measurable disease lesion by CT or MRI per RECIST v1.1 criteria. [+31]

Read more
Status: Recruiting

A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid Arthritis

A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 \[proposed etanercept biosimilar\] to Enbrel® \[EU-sourced\] in rheumatoid arthritis

Participants needed: 458
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: mAbxience Research S.L.Updated: Mar 24, 2025Locations: 60
Eligibility criteria

Documented history of RA diagnosis consistent with the 2010 ACR/EULAR classifica... [+15]

Read more